New drug combo tested for Tough-to-Treat blood cancer
Disease control
Recruiting now
This early-stage study is testing a new drug called CHO-H01, both by itself and combined with an existing drug (lenalidomide), for people with non-Hodgkin lymphoma that has returned or not responded to other treatments. The first part checks the safety and best dose of CHO-H01. T…
Phase: PHASE1, PHASE2 • Sponsor: Cho Pharma Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC